Systemic juvenile idiopathic arthritis (sJIA), formerly called Still’s disease, is officially classified as a subset of juvenile idiopathic arthritis (JIA).
Taken from the International Journal of Inflammation
Volume 2012 (2012), Article ID 480373, 5 pages
IL-18 Serum Level in Adult Onset Still’s Disease: A Marker of Disease Activity
Adult Onset Still’s Disease and Inflammation
Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety.
FULL ARTICLE through NBCI – NIH.gov
Retrospective study of 61 patients with adult-onset Still’s disease admitted with fever of unknown origin in China.
Abstract published at PubMed.gov
(The article states, ‘AOSD was not a rare reason of FUO in eastern China.’)
Fever of unknown origin: a review of 20 patients with adult-onset Still’s disease.
Abstract published on NIH.gov PubMed.gov
Scientists have discovered how to ‘switch off’ autoimmune diseases.
- How Digital Healthcare can Help the Environment, Reduce Costs, and Improve Patient Service via Tech Net Magazine (Microsoft)
- The Hyperferritinemia Syndrome: macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome This article is from the BMC Medicine Site
- T cell subsets and their role in the pathogenesis of rheumatic disease. Taken from: the Current Opinion in Rheumatology site.
Latest Clinical Trials in Rheumatoid Arthritis
- To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)
- An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate
- http://clinicalresearch.com for up to date trials and research on many diseases and conditions that can be located by zip code.
- UCB announces top-line phase 2 results for Olokizumab in rheumatoid arthritis Phase 2 results for Olokzumab in rheumatoid arthritis
- About Olokizumab:Olokizumab is a humanized monoclonal antibody targeting the IL-6 cytokine. IL-6 is involved in several autoimmune and inflammatory pathways. Olokizumab is the first of a new type of IL-6 inhibitor that selectively blocks the final assembly of the IL-6 receptor signaling complex.
- Genomic study: Why children in remission from rheumatoid arthritis experience recurrences Cited from: Aug 29, Arthritis & Rheumatism
- Reg4ALL to enter you and, if chosen, your families medical information. Share with whom or where you want. You choose the level of privacy. A chance for researchers and doctors to find and register your conditions and information about Still’s disease. You to choose how and if you wish to participate in future studies or research projects. Sponsored by the Genetic Alliance organization through DiseaseinfoSearch
- C-reactive protein test Aug. 16, 2013 – C-reactive protein test — Overview covers what to expect and results from this blood test.
- Interactive Slideshows such as: Is there an RA diet? Day & Night: 24 Hours with RA, 10 Things to Know About RA. View any/all at: www.arthritis.org/slideshows Presented by the Arthritis Foundation
- Tissue damage could be behind pain in hip implants Cited from the Arthritis Digest, April 10, 2013
- New rheumatoid arthritis drug has poor results in trials Cited from the Arthritis Digest April 9 2013
- FDA Has Approved Il-1 Inhibitor Canakinumab for Systemic JIA The Journal of Musculoskeletal Medicine, May 10, 2013 EntreMed’s 2ME2 receives US patent for treatment of rheumatoid diseases: Pharmabiz.com
- Rheumatoid Arthritis: Can it affect the eyes? Article and information from Mayo Clinic.com Health
- How Juvenile Arthritis Affects the Eyes This article will give you information about how juvenile arthritis can cause eye problems – including uveitis — and what can be done to protect your child’s eyes. Web MD
- Treatment wth Infliximab (Remicade)
- Is Still’s Disease An Auto-inflammatory Syndrome ( PDF format)
- IL-18 Serum Level in Adult Onset Still’s Disease A Marker of Disease Activity (PDF format)
- Dr. Cush Article: Adult-Onset Still’s Disease: A Circadian Cytokine Syndrome? Probably one of the most informative documents on Still’s disease you will ever come across. Dr. Cush is a highly respected Rheumatologist and very knowledgeable on Adult- Onset Still’s disease. This article is approx. 30 pages.
- Clinical And Laboratory Features And Treatment
- Successful treatment of a small cohort of patients with adult onset of Still’s disease with infliximab (Remicade): first experiences
- Additional Article from Dr. Cush: Bulletin on the Rheumatic Diseases: Adult-Onset Still’s Disease( Smaller article app. 4 pages)
- Miller Fisher syndrome in adult onset Still’s disease: case report and review of the literature of other neurological manifestations
- Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP) complicating adult Still’s disease: remission induced with intravenous immunoglobulin G